Browsing Tag
Paradigm Biopharmaceuticals
2 posts
Paradigm Biopharmaceuticals (ASX: PAR) hits key Phase 3 milestone as dosing begins in U.S. and Australia
Paradigm Biopharmaceuticals (ASX: PAR) begins dosing in its pivotal Phase 3 osteoarthritis trial, setting up a mid-2026 data readout that could redefine its future.
Paradigm Biopharmaceuticals scores A$16m investment—Here’s what it means for osteoarthritis treatment
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) has secured a significant A$16 million in funding, positioning the company to launch…